NRG-GY012: A Randomized Phase II Study Comparing Single-Agent Olaparib, Single Agent Cediranib, and the Combination of Cediranib/Olaparib in Women with Recurrent, Persistent or Metastatic Endometrial Cancer.

Is this Study for You?

Let's Get Started!



Type of Study



Harmony Campus
Memorial Hospital Central
Memorial Hospital North
University of Colorado Hospital

Principal Investigator
Photograph of Kian Behbakht,  MD, MBA

Kian Behbakht, MD, MBA

Study ID

Protocol Number: 18-2281

More information available at NCT03660826

Is this Study for You?

Let's Get Started!

Not finding the right Study for you? Join ResearchMatch, a nation-wide registry connecting volunteers and researchers